Abstract. The trefoil factor (TFF) family comprises three thermo-stable and protease-resistant proteins (TFF1, TFF2 and TFF3) and plays an essential role in gastrointestinal mucosa protection and regeneration, and TFFs have recently been found to be involved in the development and progression of various types of cancer. However, the clinical significance of TFFs in colorectal cancer (CRC) patients remains unclear. The present study determined the relationship between TFF expression and clinicopathological findings, as well as longterm outcome in CRC patients. The mRNA expression levels of TFFs were examined in the excised CRC specimens obtained from 154 consecutive CRC patients who underwent surgical resection between 2005 and 2007 at our institution. TFF3 expression was significantly associated with the presence of distant metastasis (p=0.017), although neither TFF1 nor TFF2 expression was associated with the clinicopathological features. Survival rate of the patients with positive TFF3 was significantly worse compared to those with negative TFF3 (p=0.011). A multivariate analysis revealed that the expression of TFF3, lymph node metastasis, and vascular invasion were independent prognostic factors for disease-specific survival. Furthermore, among 134 patients with no clinical findings of metastasis at surgery, the patients with positive TFF3 experienced recurrence within one year more frequently than those with negative TFF3 (p=0.039). In conclusion, TFF3 is not only a useful biomarker for a long-term surgical result in CRC patient, but also may be a risk factor of early recurrence.
Introduction
Colorectal cancer (CRC) is the fourth leading cause of cancerrelated mortality worldwide, accounting for over 600,000 deaths annually (1) . Although surgical resection is the most powerful treatment for the complete cure of CRC, a local or distant tumor recurrence sometimes develops even after a curative resection of the primary tumor is achieved. Therefore, the identification of reliable criteria and/or novel biomarkers for predicting a risk of recurrence is needed to identify the patients who should receive postoperative adjuvant chemotherapy. Recent clinical trials and basic research have designed to investigate biomolecules available as prognostic factors (2) . However, none of them have been incorporated into the clinical practice to assess patients with CRC.
The trefoil factor (TFF) proteins (TFF1, TFF2 and TFF3) are characterized by the presence of at least one 40-aminoacid protein domain with three conserved disulfide bonds, which is termed the trefoil motif (3, 4) . TFF1 and TFF2 are usually expressed in the stomach and duodenal epithelium, respectively. TFF3 is predominantly expressed in the goblet cells of the small intestine and colon (4) . TFFs are rapidly and coordinately secreted from mucus-secreting cells when the gastrointestinal mucosa suffers mechanical and/or chemical damage, and they respond to the mucosal injury (4, 5) . Recent studies suggest that TFFs are involved in the development and progression of various types of cancer, including breast, lung, prostate, stomach and colon cancer (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . In general, TFF1 seems to function as a stomach-specific tumor suppressor gene (16, 17) , whereas TFF2 and TFF3 are thought to augment tumor progression by increasing tumor invasion and metastasis (16, 18) . However, the more precise role of TFFs in human cancer remains unclear. There are few reports on studies that investigated the clinical significance of TFFs expression using excised primary CRC specimens (19) . In the present study, we evaluated the mRNA expression levels of TFF1, TFF2 and TFF3 in excised CRC specimens and assessed the correlation between TFF expression and the clinicopathological findings in CRC patients. Immunohistochemistry. The paraffin-embedded sections were incubated with anti-TFF3 antibody [Human TFF3 monoclonal antibody (M01), clone 3D9, 1:500; Abnova Corp., Taipei, Taiwan] overnight at 4˚C and with the corresponding secondary antibody for 30 min at room temperature. The slides were then washed in phosphate-buffered saline (pbS), followed by incubation with a DAb (3,3'-diaminobenzidine) substrate kit (Nichirei Co., Tokyo, Japan). Tumors with either cytoplasmic or both cytoplasmic and membranous staining were considered to be positive for TFF3, and the level of staining was scored according to a comprehensive scoring formula previously described (21) . briefly, the intensity of staining was scored as follows: zero, no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. The extent of staining was scored as follows: zero, no positively stained cells; 1, <33% of the tumor cells had positive staining; 2, 33-67% positively stained tumor cells; and 3, >67% tumor cells with positive staining. Tumors with a total score higher than six were considered to have high TFF3 expression.
Materials and methods

Patients
Statistical analysis. Statistical analyses were performed using the computer software SpSS 15.0J for windows program (SpSS, Inc., Chicago, IL, USA). Comparisons of clinical variables between the two groups were performed with the MannWhitney U-tests. Comparisons of categorical data between the two groups were performed with Chi-square tests. A cut-off value for the TFF3 expression status was determined using a receiver-operator characteristic (ROC) curve. The survival curves were generated using the Kaplan-Meier method, and statistical differences were compared using log-rank tests. both univariate and multivariate analyses for survival were performed using Cox's proportional hazards model. p-values <0.05 were considered statistically significant.
Results
Patient characteristics. The characteristics of the patients and their TFF expression levels are summarized in Table I Relationship between TFF expression and the clinicopathological findings in CRC patients. The expression status of each patient's TFF was classified into a high-or low-expression group. For the purpose of the statistical analysis, the median of this series was used as a cut-off value to distinguish tumors with high or low TFF expression. As shown in Table I , neither TFF1 nor TFF2 expression was associated with the tumor histology, depth of cancer invasion, lymph node metastasis, lymphatic invasion or vascular invasion. Conversely, expression status of TFF3 was significantly associated with the location of the disease and the presence of distant metastasis (p=0.016 and 0.017, respectively). In addition, the expression level of TFF3 in cancer tissue was significantly higher than that of the corresponding normal tissue (p=0.001) (Fig. 1) .
Immunohistochemical staining for TFF3. The immunohistochemical staining for TFF3 was predominantly distributed in the cytoplasm of cancer cells. Fig. 2A and b indicates low TFF3 expression, while Fig. 2C and D depicts high TFF3 expression. The immunohistochemical staining status of TFF3 was significantly correlated with the corresponding mRNA expression level (data not shown).
Definition of the cut-off value for TFF3 expression status. The TFF3 expression status was re-classified into positive-and negative-expression groups using the appropriate cut-off value that was determined by a ROC curve generated according to the presence of distant metastasis. The cut-off value was determined to be 0.134 with 60.0% sensitivity and 73.1% specificity [area under the curve (AUC) 0.662, 95% CI 0.531-0.793, p=0.020]. Forty-eight patients were classified as belonging to the positive expression group, while the remaining 106 patients were included in the negative expression group.
Kaplan-Meier survival analysis according to TFF3 expression. The Kaplan-Meier survival analysis with log-rank tests revealed a strong correlation between TFF3 expression and disease-specific survival (Fig. 3) . The patients with positive TFF3 expression (n=48) had a significantly shorter survival than those who were negative for TFF3 (p=0.011).
Univariate and multivariate analyses for disease-specific survival in 154 CRC patients. As summarized in Table II , tumor histology [hazard ratio (HR)=2.827, p=0.004), cancer Table I . Relationship between TFF family expression and clinicopathological findings. Table II . Statistical analysis of disease-specific survival of colorectal patients (n=154). 
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Discussion
This is the first report demonstrating that positive TFF3 expression could be a prognostic marker for recurrence in CRC patients who underwent curative resection by using the excised specimens. The TFF proteins are widely expressed in the gastrointestinal epithelium, and they are well known for their protective and healing effects after mucosal damage in the gastrointestinal tract (4, 5) . TFFs protect cells from apoptotic death and stimulate cell migration to achieve their role in epithelial tissue (22, 23) . Although most studies have focused on their effects following mucosal injury, recent evidence has indicated that TFFs contribute to the oncogenic transformation, growth and metastasis of human solid tumors (21, (24) (25) (26) . However, to the best of our knowledge, the role of TFF expression in CRC has never been investigated in excised specimens. The present study evaluated the expression status of TFFs in a large cohort of samples from patients with CRC. Our results demonstrate the clinical significance of TFFs and highlight their potential as therapeutic targets in CRC patients. TFF1 was initially described as an estrogen-inducible gene in the hormone-sensitive breast cancer cell line MCF-7 (27) . However, a later observation that TFF1 knockout mice develop gastric adenomas and adenocarcinomas indicated the role of TFF1 as a tumor suppressor in the stomach (16) . Our present study also demonstrated that loss of TFF1 expression in gastric cancer contributed to tumor invasion and was associated with poor survival (17) . TFF1 is absent in normal colon tissue but is induced at high levels in CRCs (28). Rodrigues et al (29) demonstrated that forced TFF1 expression promotes adenomacarcinoma transition in human colon epithelial cells by using premalignant adenoma cells. In this series, TFF1 expression status was not associated with clinicopathological findings such as tumor histology, cancer invasion depth and lymph node metastasis (Table I) . One previous study reported that TFF1 does not have any clinicopathological significance in CRCs (30) . Taken together, the existing evidence seems to indicate that TFF1 is involved in the development of CRC rather than its progression.
The role of TFF2 in cancer biology remains unclear. Kosriwong et al (31) showed that positive TFF2 immunostaining in cholangiocarcinoma was markedly increased compared with normal and precancerous tissues, thus, suggesting that it plays an important role in tumor progression. In contrast, another study demonstrated that Helicobacter pylori infection promotes hypermethylation of the TFF2 promoter and silencing of TFF2 expression during gastric carcinogenesis, indicating that it acts as a tumor-suppressor gene (32) . Therefore, the role of TFF2 in human malignancies has been controversial so far and relationship between TFF2 expression and the clinical parameters of CRCs unknown. Similarly, in our data, clinical values of TFF2 in patients with CRC are still obscure.
TFF3 is upregulated in most human malignancies, including CRC. Yio et al (12) demonstrated that TFF3 contributes to the aggressive behavior of colon cancer cells in a rat model. Rat colon cancer cells that natively express TFF3 showed enhanced migration and invasion and less apoptosis compared with a sister cell line that does not express TFF3. In cooperation with vascular endothelial growth factor (VEGF), TFF3 activates the signal transducer and activator of transcription (STAT) 3 signaling pathway, which promotes cellular invasion and tumor growth in human colon cancer (33) . In the present study, high TFF3 expression was significantly associated with the presence of distant metastasis, including liver metastasis, lung metastasis, para-aortic lymph node metastasis and peritoneal dissemination (Table I) , thus, indicating that TFF3 promotes the aggressive behavior of CRC. In addition, TFF3 expression was significantly higher in cancer tissues compared to the corresponding normal mucosa both at the mRNA level (p=0.001; Fig. 1 ) and protein level (Fig. 2) . The survival analysis demonstrated that patients with positive TFF3 expression showed significantly worse survival than those who were negative for TFF3 (p=0.011; Fig. 3) . Furthermore, the prognostic value of TFF3 in CRC patients was identified as an independent prognostic factor in a multivariate analysis (p=0.009; Table II) . Moreover, one recent study demonstrated a relationship between TFF3 expression and lymph node metastasis and concluded that TFF3 expression might play a role in promoting lymph node metastases of CRCs (19) . Another group found that TFF3 was frequently expressed in both primary colon cancer and liver metastases but not in normal liver tissue (13) . Taken together, the results suggest that TFF3 is associated with patient survival and the metastatic potential of CRC. Thus, TFF3 might be a possible prognostic marker for disease recurrence after curative surgery. We performed an additional statistical analysis that included the 134 patients without metastatic disease at the time of surgery. Among the 134 CRC patients who received curative surgery, patients with positive TFF3 expression exhibited a significantly higher recurrence frequency within one year in compared with those with negative TFF3. Although further studies of additional cohorts are needed, our results clearly demonstrate the prognostic potential of TFF3 for early CRC recurrence in a clinical setting.
In conclusion, positive TFF3 expression is an independent poor-prognostic factor in CRC patients, and may be a useful marker for early recurrence. 
